Abstract
Esophageal carcinoma (EC) is a global health problem, with disappointing 5-year survival rates of only 15–25%. Near-infrared targeted photodynamic therapy (NIR-tPDT) is a novel strategy in which cancer-targeted phototoxicity is able to selectively treat malignant cells. In this in vitro report we demonstrate the applicability of antibody-based NIR-tPDT in esophageal adenocarcinoma (EAC), using the phototoxic compounds cetuximab-IRDye700DX and trastuzumab-IRDye700DX, targeting respectively epidermal growth factor receptor 1 (EGFR) and 2 (HER2). Furthermore, we demonstrate that NIR-tPDT can be made more effective by tyrosine kinase inhibitor (TKI) induced growth receptor upregulation. Together, these results unveil a novel strategy for non-invasive EAC treatment, and by pretreatment-induced receptor upregulation its future clinical application may be optimized.
Highlights
Esophageal cancer (EC) is a global health problem
Near-infrared targeted photodynamic therapy (NIR-tPDT) is a novel strategy in which cancer-targeted phototoxicity is able to selectively treat malignant cells. In this in vitro report we demonstrate the applicability of antibody-based NIR-tPDT in esophageal adenocarcinoma (EAC), using the phototoxic compounds cetuximab-IRDye700DX and trastuzumab-IRDye700DX, targeting respectively epidermal growth factor receptor 1 (EGFR) and 2 (HER2)
Www.impactjournals.com/oncotarget tPDT seems a promising treatment option for esophageal adenocarcinoma and that tyrosine kinase inhibitor (TKI) pretreatment is able to optimize the therapeutic effect of this novel cancerselective treatment, making it interesting for future clinical translation
Summary
Esophageal cancer (EC) is a global health problem. EC is the sixth leading cause of cancer related mortality and the eighth most commonly diagnosed cancer in the world [1]. Over the past few decades risk factors such as obesity and gastroesophageal reflux disease (GERD), which are both progressive problems of the Western countries, have caused the incidence rates of EAC to increase [2]. When EAC is in its limited disease-stage, superficial and still restricted to the mucosa, non-invasive endoscopic resection is the treatment of choice [7]. To optimally treat early stage EAC with positive margins after endoscopic resection, additive treatment approaches are needed. Previous research has focused on implementing PDT as an alternative treatment option for early stage EAC and dysplastic Barrett Esophagus (BE) [8]. To date, PDT is considered an effective salvage treatment option for patients www.impactjournals.com/oncotarget who are not fit for surgery, rather than as a first choice of treatment in early EAC or dysplastic BE in general [12]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
